2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Pancreatic Neoplasms
7
Breast Neoplasms
5
Radiation Fibrosis Syndrome
3
Pancreatic Adenocarcinoma
2
Lung Neoplasms
2
Glioblastoma
2
Thrombocytosis
1
Stomatitis
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Peripheral Nervous System Diseases
1
Pancreatic Ductal Adenocarcinoma
1
Osteosarcoma
1
Neuroma, Acoustic
1
Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Interventions
Standard of Care
8
Surveys and Questionnaires
7
COVID-19 Vaccines
6
Blood Specimen Collection
6
BNT162 Vaccine
6
Specimen Handling
5
2019-nCoV Vaccine mRNA-1273
5
Hydroxychloroquine
4
Surgical Procedures, Operative
3
Practice Guidelines as Topic
3
tocilizumab
2
sotrovimab
2
sinovac COVID-19 vaccine
2
cilgavimab and tixagevimab drug combination
2
Sodium Chloride
2
Pandemic Preparedness
2
Data Collection
2
CVnCoV COVID-19 vaccine
2
COH04S1 COVID-19 vaccine
2
Azithromycin
2
selinexor
1
remdesivir
1
regorafenib
1
proxalutamide
1
palbociclib
1
ogalvibart
1
monalizumab
1
lenzilumab
1
heterologous prime boost COVID-19 vaccination
1
crexavibart
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
COVID-19
×
Losartan
×
Clear all
NCT04447235
2022-08-09
TITAN
Instituto do Cancer do Estado de São Paulo
Phase 2
Terminated
77 enrolled